Bone Metabolism Tests Market Report 2025

The bone metabolism tests market size has grown strongly in recent years. It will grow from $1.9 billion in 2024 to $2.06 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period was driven by an increase in osteoporosis diagnosis rates, greater awareness of bone-related disorders, a rising number of postmenopausal women, wider adoption of DEXA scans, and a growing aging population.

The bone metabolism tests market size is expected to see strong growth in the next few years. It will grow to $2.8 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth projected for the forecast period is attributed to the increasing need for early detection of bone disorders, higher adoption of personalized treatment approaches, a stronger emphasis on preventive healthcare, the expansion of home-based diagnostic testing, and greater availability of reimbursement for diagnostic tests. Key trends expected in the forecast period include technological advancements in imaging modalities, innovation in molecular testing techniques, increased investment in research and development, the emergence of AI-powered diagnostic platforms, and progress in point-of-care bone testing tools.

The rising prevalence of osteoporosis and osteopenia is driving the growth of the bone metabolism tests market due to increasing bone fragility and the need for early diagnostic monitoring. Osteoporosis and osteopenia are musculoskeletal disorders characterized by low bone density and deterioration of bone tissue, leading to greater fragility and fracture risk, particularly among older adults. Their prevalence is increasing as aging populations experience accelerated bone loss, reducing bone density. Bone metabolism tests help identify and monitor osteoporosis and osteopenia by assessing markers of bone formation and breakdown. They provide essential insight into bone turnover, supporting timely intervention and treatment planning. For example, in June 2024, the Australian Institute of Health and Welfare (AIHW), an Australian government statutory agency, reported that osteoporosis was responsible for 2,659 deaths, equivalent to 10.2 deaths per 100,000 population in 2022, accounting for 1.4% of all deaths. Therefore, the growing prevalence of osteoporosis and osteopenia is boosting the demand for bone metabolism tests.

Key companies in the bone metabolism tests market are developing advanced solutions such as blood-based diagnostic tools to enable earlier, less invasive, and more precise detection of bone disorders. These tools use blood samples to identify biomarkers associated with various health conditions. For bone health, they detect changes in bone formation and resorption, allowing early and non-invasive diagnosis. For instance, in September 2022, University Hospitals of Geneva and the University of Geneva in Switzerland introduced a new device for diagnosing bone fragility, approved for marketing in the European Economic Area and Switzerland, with CE marking. This device measures periostin (k-POSTN), a protein linked to bone strength, through a blood test, delivering a more specific diagnosis compared to current imaging techniques such as bone densitometry. It helps identify individuals at risk of osteoporotic fractures, including those with type 2 diabetes, facilitating early therapeutic intervention to improve patient outcomes.

In February 2025, SimonMed, a US-based outpatient medical imaging provider, partnered with HeartLung Technologies to advance bone health through AI-powered early detection. The collaboration aims to strengthen preventive patient care by providing nationwide, radiation-free bone density screening through AI-driven analysis of existing CT scans. HeartLung Technologies is a US-based provider of imaging-based bone density screening.

Major players in the bone metabolism tests market are F. Hoffmann-La Roche AG, Abbott Laboratories, Siemens Healthineers AG, Laboratory Corporation of America Holdings (LabCorp), Hologic Inc., bioMérieux SA, QuidelOrtho Corporation, Beckman Coulter Inc., Bio-Rad Laboratories Inc., DiaSorin S.p.A., Takara Bio Inc., Randox Laboratories Ltd., Trivitron Healthcare Pvt. Ltd., MESO SCALE DIAGNOSTICS LLC, Immunodiagnostic Systems plc, DMS Imaging SA, Creative Diagnostics, Oxford Biosystems Ltd., Epitope Diagnostics Inc., Maccura Biotechnology Co. Ltd.

North America was the largest region in the bone metabolism tests market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bone metabolism tests market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bone metabolism tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Bone metabolism tests are laboratory examinations that evaluate the balance between bone formation and bone breakdown. They measure specific markers in blood or urine such as alkaline phosphatase and osteocalcin for bone formation, and CTX or NTX for bone resorption to assess bone health, diagnose metabolic bone disorders, and monitor treatment effectiveness.

The main categories of bone metabolism tests include biochemical tests, imaging tests, bone density assessments, histomorphometry, and molecular testing. Biochemical tests detect markers in blood or urine that indicate bone turnover, whereas imaging and bone density assessments help evaluate bone structure and mineral content. The product consists of assays or consumables and instruments utilizing various technologies, such as enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and others. It is used in multiple applications such as osteoporosis diagnosis, bone disease diagnosis, fracture risk evaluation, drug development, and clinical research, and is adopted by several end users, including hospitals, diagnostic laboratories, research institutes, home care settings, and academic institutions.

The bone metabolism tests market research report is one of a series of new reports that provides bone metabolism tests market statistics, including the bone metabolism tests industry global market size, regional shares, competitors with the bone metabolism tests market share, detailed bone metabolism tests market segments, market trends, and opportunities, and any further data you may need to thrive in the bone metabolism tests industry. This bone metabolism tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bone metabolism tests market consists of revenues earned by entities by providing services such as sample collection and processing, test result interpretation, patient screening consultations, diagnostic panel customization, and remote test accessibility. The market value includes the value of related goods sold by the service provider or included within the service offering. The bone metabolism tests market includes sales of analyzers, calibration standards, patient-specific reporting software, quality control reagents, and at-home test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.